Top Markets
Coin of the day
WPD Pharmaceuticals Inc. WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc.

WBIO
Kedudukan dalam Saham #34463
WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver,... WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.
Harga Saham
$0.04895618
Disegerakkan terakhir: 2025-03-18
Modal Pasaran
$5.55M
Perubahan (1 hari)
-0.04%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan WPD Pharmaceuticals Inc. (WBIO)

Kategori

Hasil untuk WPD Pharmaceuticals Inc. (WBIO)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada WPD Pharmaceuticals Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi WPD Pharmaceuticals Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE